ConductScience.org, home

Paper31754328

Current Progress in CAR-T Cell Therapy for Solid Tumors.

Ma S and 7 others. Int J Biol Sci, 2019. Cited by 403 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Current Progress in CAR-T Cell Therapy for Solid Tumors. Papers, record 31754328. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31754328

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Current Progress in CAR-T Cell Therapy for Solid Tumors.
PubMed
Journal
Int J Biol Sci
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
403
iCite
Relative citation ratio, by iCite
14.4
iCite
Revised in PubMed
2020-07-06
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ma SShuo
2Li XXinchun
3Wang XXinyue
4Cheng LLiang
5Li ZZhong
6Zhang CChangzheng
7Ye ZZhenlong
8Qian QQijun

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunotherapy, AdoptiveMajor topic
NeoplasmsMajor topic
Cytokine Release Syndrome
Cytokines
Humans
Treatment Outcome
Tumor Microenvironment

Source PubMed

References115

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120,981,101The patterns and dynamics of genomic instability in metastatic pancreatic cancer.Nature2010https://conductscience.org/library/papers/20981101PubMed
212,509,765Targeting tumours with genetically enhanced T lymphocytes.Nat Rev Cancer2003https://conductscience.org/library/papers/12509765PubMed
312,427,307Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.Hum Gene Ther2002https://conductscience.org/library/papers/12427307PubMed
429,880,908Driving cars to the clinic for solid tumors.Gene Ther2018https://conductscience.org/library/papers/29880908PubMed
524,876,563Current concepts in the diagnosis and management of cytokine release syndrome.Blood2014https://conductscience.org/library/papers/24876563PubMed
618,559,619Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.Clin Cancer Res2008https://conductscience.org/library/papers/18559619PubMed
728,405,515PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.Oncoimmunology2017https://conductscience.org/library/papers/28405515PubMed
817,108,138CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.Cancer Res2006https://conductscience.org/library/papers/17108138PubMed
927,009,301Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Sci China Life Sci2016https://conductscience.org/library/papers/27009301PubMed
1028,929,447Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells.Protein Cell2017https://conductscience.org/library/papers/28929447PubMed
1126,110,321Seatbelts in CAR therapy: How Safe Are CARS?Pharmaceuticals (Basel)2015https://conductscience.org/library/papers/26110321PubMed
1223,839,099TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.Mol Ther Nucleic Acids2013https://conductscience.org/library/papers/23839099PubMed
1327,145,284Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.Oncotarget2016https://conductscience.org/library/papers/27145284PubMed
1423,939,024Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.Mol Ther2013https://conductscience.org/library/papers/23939024PubMed
1518,767,947EGF receptor variant III as a target antigen for tumor immunotherapy.Expert Rev Vaccines2008https://conductscience.org/library/papers/18767947PubMed
1619,384,291Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.Mol Ther2009https://conductscience.org/library/papers/19384291PubMed
1724,409,448Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.Cancer Immunol Res2013https://conductscience.org/library/papers/24409448PubMed
1829,104,305Full-length antibodies versus single-chain antibody fragments for a selective impedimetric lectin-based glycoprofiling of prostate specific antigen.Electrochim Acta2017https://conductscience.org/library/papers/29104305PubMed
1926,330,164Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.Cancer Res2015https://conductscience.org/library/papers/26330164PubMed
2024,277,834Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.Proc Natl Acad Sci U S A2013https://conductscience.org/library/papers/24277834PubMed

See all 115 references

Cited by313

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 403 citations.

PMIDTitleJournalYearIn PapersSource
42,856,948Adoptive cell therapy in lung cancer: progress, challenges, and prospects.Chin Med J Pulm Crit Care Med2026https://conductscience.org/library/papers/42856948PubMed
42,819,907Adoptive T Cell therapy for cancer and autoimmune disease: current advances, challenges, and future directions.Oncol Rev2026https://conductscience.org/library/papers/42819907PubMed
42,819,036The GPR183-oxysterol axis in cancer: immune trafficking, spatial organization, and therapeutic potential.Front Immunol2026https://conductscience.org/library/papers/42819036PubMed
42,780,345The mechanism of breast cancer stem cells and tumor microenvironment promoting radioresistance in breast cancer and its intervention strategies.Front Immunol2026https://conductscience.org/library/papers/42780345PubMed
42,754,891Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers.Mol Cancer2026https://conductscience.org/library/papers/42754891PubMed
42,741,434Novel cryopreservation medium for enhanced stability of T cells at -80°C.Front Hematol2024https://conductscience.org/library/papers/42741434PubMed
42,729,542The dual roles of Prevotella in gastrointestinal tumorigenesis: from molecular mechanisms to therapeutic prospects.Front Oncol2026https://conductscience.org/library/papers/42729542PubMed
42,630,534Clinical significance of SNRPD1 expression in predicting post-transplant recurrence of hepatocellular carcinoma.Am J Transl Res2026https://conductscience.org/library/papers/42630534PubMed
42,558,624Targeting NOP14 remodels the tumor immune microenvironment and enhances the antitumor efficacy of PD-1 blockade in DLBCL.Front Immunol2026https://conductscience.org/library/papers/42558624PubMed
42,482,408Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions.Cancer2026https://conductscience.org/library/papers/42482408PubMed
42,441,043A narrative review of new strategies for immunotherapy combination treatment in platinum-resistant ovarian cancer: mechanisms, clinical evidence, and future directions.Front Oncol2026https://conductscience.org/library/papers/42441043PubMed
42,353,619Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42353619PubMed
42,332,855A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma.Med Sci Monit2026https://conductscience.org/library/papers/42332855PubMed
42,329,489Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.Curr Treat Options Oncol2026https://conductscience.org/library/papers/42329489PubMed
42,311,657The cGAS-STING pathway in cancer immunotherapy: prognostic value and therapeutic potential.Front Immunol2026https://conductscience.org/library/papers/42311657PubMed
42,163,764Advances in Biomarkers for CAR-T Treatment Resistance in Diffuse Large B-Cell Lymphoma.Mini Rev Med Chem2026https://conductscience.org/library/papers/42163764PubMed
42,116,871Customized Marketing Strategies for Cancer Immunocyte Therapy Based on its Distinctive Attributes.Cancer Manag Res2026https://conductscience.org/library/papers/42116871PubMed
42,113,250Mechanical preconditioning by shear stress enhances memory formation and anti-tumor function of CAR-T cells.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42113250PubMed
42,099,215Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study.Technol Cancer Res Treat2026https://conductscience.org/library/papers/42099215PubMed
42,088,834Remodeling memory T cells with chemotherapy and immune checkpoint inhibitors as host pre-conditioning to empower in vivo CAR-T therapy.Synth Syst Biotechnol2026https://conductscience.org/library/papers/42088834PubMed

See all 313 cited by

Genes58

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
BCL2L1598PubTator's text mininghttps://conductscience.org/library/genes/598NCBI Gene
CASP9842PubTator's text mininghttps://conductscience.org/library/genes/842NCBI Gene
CCL176,361PubTator's text mininghttps://conductscience.org/library/genes/6361NCBI Gene
CCL196,363PubTator's text mininghttps://conductscience.org/library/genes/6363NCBI Gene
CCR2729,230PubTator's text mininghttps://conductscience.org/library/genes/729230NCBI Gene
CCR41,233PubTator's text mininghttps://conductscience.org/library/genes/1233NCBI Gene
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD24451,744PubTator's text mininghttps://conductscience.org/library/genes/51744NCBI Gene
CD247919PubTator's text mininghttps://conductscience.org/library/genes/919NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
CD44960PubTator's text mininghttps://conductscience.org/library/genes/960NCBI Gene
CD80941PubTator's text mininghttps://conductscience.org/library/genes/941NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CEACAM31,084PubTator's text mininghttps://conductscience.org/library/genes/1084NCBI Gene
CSF21,437PubTator's text mininghttps://conductscience.org/library/genes/1437NCBI Gene
CTLA41,493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
CXADRP1653,108PubTator's text mininghttps://conductscience.org/library/genes/653108NCBI Gene

See all 58 genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31754328

GET https://conductscience.org/api/papers/v1/31754328/references?page=2